MENNA, PIERANTONIO

MENNA, PIERANTONIO  

Facoltà Dipartimentale di Scienze e Tecnologie per l'Uomo e l'Ambiente  

Mostra records
Risultati 1 - 20 di 90 (tempo di esecuzione: 0.165 secondi).
Titolo Data di pubblicazione Autore(i) File
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 1-gen-2009 Menna, P; Salvatorelli, E; Minotti, G
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 1-gen-2001 Minotti, G; Ronchi, R.; Menna, P.; Cairo, G.
An introduction to the metabolic determinants of anthracycline cardiotoxicity 1-gen-2007 Menna, P; Recalcati, S; Cairo, G; Minotti, G
Anthracycline Cardiotoxicity 1-gen-2008 Menna, P.; Salvatorelli, E.; Gianni, L.; Minotti, G
Anthracycline Cardiotoxicity 1-gen-2012 Menna, P; Gonzalez Paz, O; Chello, M; Covino, E; Salvatorelli, E; Minotti, G
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 1-gen-2010 Menna, P; Salvatorelli, E; Minotti, G
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 1-gen-2000 Minotti, G.; Licata, S.; Saponiero, A.; Menna, P; Calafiore, A. M.; Di Giammarco, G.; Liberi, G.; Animati, F.; Cipollone, A.; Mancini, S.; Maggi, C. A.
Anthracyclines 1-gen-2008 Minotti, G; Salvatorelli, E; Menna, P
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 1-gen-2023 Minotti, Giorgio; Salvatorelli, Emanuela; Menna, Pierantonio
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 1-gen-2004 Minotti, G; Menna, P; Salvatorelli, E; Cairo, G; Gianni, L.
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 1-gen-2022 Minotti, Giorgio; Menna, Pierantonio; Camilli, Massimiliano; Salvatorelli, Emanuela; Levi, Roberto
Cancer drugs and QT prolongation: weighing risk against benefit 1-gen-2017 Menna, P.; Salvatorelli, E; Minotti, G.
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 1-gen-2022 Minotti, Giorgio; Salvatorelli, Emanuela; Reggiardo, Giorgio; Mangiacapra, Fabio; Camilli, Massimiliano; Menna, Pierantonio
Cardio-oncology in clinical studies and real life 1-gen-2019 Dent, Sf; Suter, Tm; López-Fernández, T; Opolski, G; Menna, P; Minotti, G
Cardiotoxicity of antitumor drugs 1-gen-2008 Menna, P; Salvatorelli, E; Minotti, G
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 1-gen-2019 Menna, P; Minotti, G; Salvatorelli, E.
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 1-gen-2011 Cacciapaglia F, F.; Navarini, L.; Menna, P.; Salvatorelli, E.; Minotti, G; Afeltra, A.
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 1-gen-2010 Menna, P.; Salvatorelli, E.; Salsano, C.; Gianni, L.; Minotti, G.
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 1-gen-2021 Menna, P; Salvatorelli, E; Del Principe, Mi; Perrone, S; Pagano, L; Marchesi, F; Minotti, G.
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 1-gen-2003 Sacco, G.; Giampietro, R.; Salvatorelli, E.; Menna, P; Bertani, N.; Graiani, G.; Animati, F.; Goso, C.; Maggi, C. A.; Mancinis, S.; Minotti, G.